日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

长期使用替诺福韦艾拉酚胺治疗慢性乙型肝炎可获得较高的病毒抑制率,且肾脏和骨骼安全性良好。

Chan, Henry L Y; Buti, Maria; Lim, Young-Suk; Agarwal, Kosh; Marcellin, Patrick; Brunetto, Maurizia; Chuang, Wan-Long; Janssen, Harry L A; Fung, Scott; Izumi, Namiki; Abdurakhmanov, Dzhamal; Jabłkowski, Maciej; Celen, Mustafa K; Ma, Xiaoli; Caruntu, Florin; Flaherty, John F; Abramov, Frida; Wang, Hongyuan; Camus, Gregory; Osinusi, Anu; Pan, Calvin Q; Shalimar; Seto, Wai-Kay; Gane, Edward

Correction: Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core

更正:二酰甘油酰基转移酶-1将丙型肝炎病毒NS5A蛋白定位到脂滴,并增强NS5A与病毒衣壳核心的相互作用。

Camus, Gregory; Herker, Eva; Modi, Ankit A; Haas, Joel T; Ramage, Holly R; Farese, Robert V Jr; Ott, Melanie

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

瑞德西韦3期适应性COVID-19治疗试验-1(ACTT-1)的病毒耐药性分析

Hedskog, Charlotte; Rodriguez, Lauren; Roychoudhury, Pavitra; Huang, Meei-Li; Jerome, Keith R; Hao, Linhui; Ireton, Renee C; Li, Jiani; Perry, Jason K; Han, Dong; Camus, Gregory; Greninger, Alexander L; Gale, Michael Jr; Porter, Danielle P

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

早期使用瑞德西韦预防门诊新冠肺炎患者发展为重症

Gottlieb, Robert L; Vaca, Carlos E; Paredes, Roger; Mera, Jorge; Webb, Brandon J; Perez, Gilberto; Oguchi, Godson; Ryan, Pablo; Nielsen, Bibi U; Brown, Michael; Hidalgo, Ausberto; Sachdeva, Yessica; Mittal, Shilpi; Osiyemi, Olayemi; Skarbinski, Jacek; Juneja, Kavita; Hyland, Robert H; Osinusi, Anu; Chen, Shuguang; Camus, Gregory; Abdelghany, Mazin; Davies, Santosh; Behenna-Renton, Nicole; Duff, Frank; Marty, Francisco M; Katz, Morgan J; Ginde, Adit A; Brown, Samuel M; Schiffer, Joshua T; Hill, Joshua A

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment

台湾慢性丙型肝炎合并乙型肝炎患者接受雷迪帕韦/索非布韦治疗后108周的随访

Liu, Chun Jen; Sheen, I Shyan; Chen, Chi Yi; Chuang, Wan Long; Wang, Horng Yuan; Tseng, Kuo Chih; Chang, Ting Tsung; Yang, Jenny; Massetto, Benedetta; Suri, Vithika; Camus, Gregory; Jiang, Deyuan; Zhang, Fangqiu; Gaggar, Anuj; Hu, Tsung Hui; Hsu, Yu Chun; Lo, Gin Ho; Chu, Chi Jen; Chen, Jyh Jou; Peng, Cheng Yuan; Chien, Rong Nan; Chen, Pei Jer

Correction for Han et al., "In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir"

对 Han 等人的论文“丙型肝炎病毒基因型 1 至 6 临床分离株对泛基因型 NS3/4A 抑制剂 Voxilaprevir 的体外敏感性”的更正

Han, Bin; Parhy, Bandita; Lu, Julia; Zhou, Eric; Hsieh, David; Camus, Gregory; Martin, Ross; Svarovskaia, Evguenia S; Mo, Hongmei; Dvory-Sobol, Hadas

Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India

在印度进行的一项3期研究中,采用索非布韦-维帕他韦单片复方制剂,疗程12周,监测强度最低限度。

Sood, Ajit; Duseja, Ajay; Kabrawala, Mayank; Amrose, Pradeep; Goswami, Bhadadev; Chowdhury, Abhijit; Sarin, Shiv Kumar; Koshy, Abraham; Hyland, Robert H; Lu, Sophia; Camus, Gregory; Stamm, Luisa M; Brainard, Diana M; Subramanian, G Mani; Prasad, Madhura; Bhatia, Shobna; Shah, Samir R; Kapoor, Dharmesh; Shalimar; Saraswat, Vivek

In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir

丙型肝炎病毒基因型 1 至 6 临床分离株对泛基因型 NS3/4A 抑制剂伏西瑞韦的体外敏感性

Han, Bin; Parhy, Bandita; Lu, Julia; Hsieh, David; Camus, Gregory; Martin, Ross; Svarovskaia, Evguenia S; Mo, Hongmei; Dvory-Sobol, Hadas

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study

雷迪帕韦/索非布韦治疗基因1型丙型肝炎病毒感染的中国初治和经治患者:一项开放标签的3b期研究

Wei, Lai; Xie, Qing; Hou, Jin Lin; Tang, Hong; Ning, Qin; Cheng, Jun; Nan, Yuemin; Zhang, Lunli; Li, Jun; Jiang, Jianning; McNabb, Brian; Zhang, Fangqiu; Camus, Gregory; Mo, Hongmei; Osinusi, Anu; Brainard, Diana M; Gong, Guozhong; Mou, Zhuangbo; Wu, Shanming; Wang, Guiqiang; Hu, Peng; Gao, Yanhang; Jia, Jidong; Duan, Zhongping

Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals

索非布韦-维帕他韦联合利巴韦林治疗对直接抗病毒药物治疗无效的基因1型或2型丙型肝炎日本患者

Izumi, Namiki; Takehara, Tetsuo; Chayama, Kazuaki; Yatsuhashi, Hiroshi; Takaguchi, Koichi; Ide, Tatsuya; Kurosaki, Masayuki; Ueno, Yoshiyuki; Toyoda, Hidenori; Kakizaki, Satoru; Tanaka, Yasuhito; Kawakami, Yoshiiku; Enomoto, Hirayuki; Ikeda, Fusao; Jiang, Deyuan; De-Oertel, Shampa; McNabb, Brian L; Camus, Gregory; Stamm, Luisa M; Brainard, Diana M; McHutchison, John G; Mochida, Satoshi; Mizokami, Masashi